迪瑞醫療(300396.SZ):致善生物股票擬終止在新三板掛牌
格隆匯 10 月 26日丨迪瑞醫療(300396.SZ)公佈,公司於2020年10月9日在巨潮資訊網上披露了《迪瑞醫療:關於參股公司擬申請其股票在全國中小企業股份轉讓系統終止掛牌的公告》。參股公司廈門致善生物科技股份有限公司(“致善生物”)根據其業務發展及長期戰略發展規劃的需要,經其慎重考慮,致善生物擬申請其股票在全國中小企業股份轉讓系統終止掛牌。
致善生物上述事項已獲其於2020年10月26日召開的2020年第四次臨時股東大會審議通過,具體終止掛牌時間以全國中小企業股份轉讓系統批准的日期為準。
截止公告日,迪瑞醫療持有致善生物519.5萬股股份,佔致善生物總股本的15.6%,致善生物停牌前1個交易日收盤價為33.20元/股,此次致善生物股票擬終止在全國中小企業股份轉讓系統掛牌不會對迪瑞醫療的生產經營產生實質性影響,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.